Aurora Cannabis (ACB) announced that it has become aware of “a second instance of misinformation” posted on news website Investing.com. On June 18, Aurora advised the market that an article posted on Investing.com incorrectly stated that Aurora had agreed to acquire New Zealand-based MedLeaf Therapeutics. Later in the day on June 18, a second article was posted on Investing.com that incorrectly states that Aurora has entered into a strategic partnership with MediPharm GmbH for distribution of medical cannabis in Germany and other EU markets. “The company categorically denies both Investing.com articles. Aurora has not entered into any such agreements, has had no discussions with MedLeaf Therapeutics or MediPharm GmbH with respect to any business combination transaction or strategic partnership, and has not made any statements or filed any information pertaining to any such transactions. The erroneous articles posted on Investing.com state that they were generated ‘with the support of AI’ and reviewed by an editor. The company is launching an investigation into the genesis of these articles. In the meantime, Aurora confirms that it is not in possession of material non-public information and advises investors that Investing.com should not be considered a credible source of information regarding the company. Any information regarding material corporate transactions will be announced directly by the company to the market as soon as it is appropriate to do so,” Aurora stated.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on ACB:

Disclaimer & DisclosureReport an Issue